Archives

Findings seen in patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery

No improvement seen in disease progression or death, and increase seen in serious adverse events with atezolizumab + cabozantinib

Single cilta-cel infusion results in lower risk of disease progression or death compared with standard care

Improvement in radiographic progression-free survival seen for talazoparib plus enzalutamide as first-line treatment

No benefit in terms of disease-free or overall survival seen for those with muscle-invasive bladder cancer undergoing radical cystectomy

Rates of testing lower among Asian, Black, and Hispanic patients versus White patients

Direct oral anticoagulants noninferior to low-molecular-weight heparin for venous thromboembolism prevention

Incidence of primary end point ranged from reduction of about 2.8 percent to increase of about 0.5 percent

Cladosporium sp. was more commonly found in early-onset CRC, while Pseudomonas luteola, Ralstonia sp., Moraxella osloensis occurred more often in late-onset CRC

Authors say next step in research is to see if weight loss impacts cancer recurrence